Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ$8.76
Market Cap
$934.08M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
801 of 924
Rank in Industry
452 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
RCKT Insider Trading Activity
RCKT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $11,714,272 | 31 | 100 |
Related Transactions
| Wilson Martin | General Counsel | 0 | $0 | 4 | $92,902 | $-92,902 |
| Militello John | See Remarks | 0 | $0 | 9 | $222,082 | $-222,082 |
| Schwartz Jonathan David | See Remarks | 0 | $0 | 4 | $223,965 | $-223,965 |
| Patel Kinnari | See Remarks | 0 | $0 | 4 | $292,484 | $-292,484 |
| White Mark Andrew | See Remarks | 0 | $0 | 3 | $421,684 | $-421,684 |
| Shah Gaurav | CEO | 0 | $0 | 4 | $724,428 | $-724,428 |
| SOUTHWELL DAVID P | director | 0 | $0 | 2 | $1.95M | $-1.95M |
| Makker Gotham | director | 0 | $0 | 1 | $7.79M | $-7.79M |
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell …
Insider Activity of Rocket Pharmaceuticals, Inc.
Over the last 12 months, insiders at Rocket Pharmaceuticals, Inc. have bought $0 and sold $11.71M worth of Rocket Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Rocket Pharmaceuticals, Inc. have bought $16.05M and sold $15.67M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,355,932 shares for transaction amount of $20M was made by WONG RODERICK (director) on 2022‑10‑06.
List of Insider Buy and Sell Transactions, Rocket Pharmaceuticals, Inc.
| 2025-02-25 | Sale | Schwartz Jonathan David | See Remarks | 6,532 0.0062% | $10.58 | $69,109 | -6.09% | |
| 2025-02-21 | Sale | Shah Gaurav | CEO | 16,303 0.0149% | $10.58 | $172,486 | -17.53% | |
| 2025-02-21 | Sale | Patel Kinnari | See Remarks | 6,078 0.0056% | $10.58 | $64,305 | -17.53% | |
| 2025-02-21 | Sale | Wilson Martin | General Counsel | 3,222 0.0029% | $10.58 | $34,089 | -17.53% | |
| 2025-02-21 | Sale | Militello John | See Remarks | 2,737 0.0025% | $10.58 | $28,957 | -17.53% | |
| 2025-01-23 | Sale | Militello John | See Remarks | 896 0.0008% | $10.38 | $9,300 | -8.75% | |
| 2024-11-21 | Sale | Shah Gaurav | CEO | 11,091 0.0122% | $13.05 | $144,782 | -14.46% | |
| 2024-11-21 | Sale | Patel Kinnari | See Remarks | 4,588 0.005% | $13.05 | $59,892 | -14.46% | |
| 2024-11-21 | Sale | Schwartz Jonathan David | See Remarks | 3,097 0.0034% | $13.05 | $40,416 | -14.46% | |
| 2024-11-21 | Sale | Wilson Martin | General Counsel | 1,175 0.0013% | $13.05 | $15,338 | -14.46% | |
| 2024-11-21 | Sale | Militello John | See Remarks | 1,224 0.0013% | $13.05 | $15,978 | -14.46% | |
| 2024-10-31 | Sale | White Mark Andrew | See Remarks | 3,080 0.0034% | $16.63 | $51,205 | -31.59% | |
| 2024-10-31 | Sale | Militello John | See Remarks | 917 0.001% | $16.63 | $15,245 | -31.59% | |
| 2024-08-16 | Sale | Shah Gaurav | CEO | 9,650 0.0105% | $18.50 | $178,564 | -27.04% | |
| 2024-08-16 | Sale | Patel Kinnari | See Remarks | 3,989 0.0043% | $18.50 | $73,812 | -27.04% | |
| 2024-08-16 | Sale | Schwartz Jonathan David | See Remarks | 2,710 0.0029% | $18.50 | $50,135 | -27.04% | |
| 2024-08-16 | Sale | Wilson Martin | General Counsel | 1,027 0.0011% | $18.50 | $19,004 | -27.04% | |
| 2024-08-16 | Sale | Militello John | See Remarks | 1,064 0.0012% | $18.50 | $19,688 | -27.04% | |
| 2024-07-22 | Sale | Militello John | See Remarks | 812 0.0009% | $23.02 | $18,688 | -36.69% | |
| 2024-07-08 | Sale | White Mark Andrew | See Remarks | 3,026 0.0032% | $20.39 | $61,715 | -19.66% |
Total: 83
*Gray background shows transactions not older than one year
Insider Historical Profitability
21.28%
| Shah Gaurav | CEO | 772680 0.7246% | $6.77M | 1 | 11 | <0.0001% |
| Patel Kinnari | See Remarks | 444103 0.4165% | $3.89M | 2 | 8 | +84.02% |
| SOUTHWELL DAVID P | director | 114784 0.1076% | $1.01M | 1 | 5 | +4.41% |
| WONG RODERICK | director | 17628567 16.5325% | $154.43M | 1 | 0 | +5.66% |
| RTW INVESTMENTS, LP | 15460119 14.4988% | $135.43M | 3 | 1 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$7,929,017 | 58 | 21.56% | $787.18M | |
$571,084,134 | 44 | 4.33% | $988.55M | |
$97,176 | 41 | 42.84% | $802.16M | |
$530,111,731 | 35 | 8.67% | $1.09B | |
$28,907,358 | 35 | 41.41% | $899.09M |
RCKT Institutional Investors: Active Positions
| Increased Positions | 154 | +91.12% | 26M | +28.51% |
| Decreased Positions | 71 | -42.01% | 7M | -7.29% |
| New Positions | 59 | New | 10M | New |
| Sold Out Positions | 26 | Sold Out | 2M | Sold Out |
| Total Postitions | 252 | +49.11% | 112M | +21.22% |
RCKT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Rtw Investments, Lp | $167,149.00 | 16.53% | 17.69M | 0 | 0% | 2024-12-31 |
| Wellington Management Group Llp | $132,254.00 | 13.08% | 14M | +3M | +24.49% | 2024-12-31 |
| Blackrock, Inc. | $67,069.00 | 6.63% | 7.1M | +726,566 | +11.4% | 2024-12-31 |
| Vanguard Group Inc | $62,158.00 | 6.15% | 6.58M | +1M | +18.8% | 2024-12-31 |
| Maverick Capital Ltd | $49,130.00 | 4.86% | 5.2M | +1M | +26.23% | 2024-12-31 |
| Westfield Capital Management Co Lp | $44,553.00 | 4.41% | 4.71M | +220,777 | +4.91% | 2024-12-31 |
| Citadel Advisors Llc | $38,961.00 | 3.85% | 4.12M | +2M | +91.93% | 2024-12-31 |
| Janus Henderson Group Plc | $37,838.00 | 3.74% | 4M | +2M | +111.03% | 2024-12-31 |
| State Street Corp | $32,679.00 | 3.23% | 3.46M | +356,057 | +11.48% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $29,754.00 | 2.94% | 3.15M | -59,261 | -1.85% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.